TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34507866

Group type: EXPERIMENTAL
Intervention: Qualitative adjustments to communication challenges
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Qualitative adjustments to comprehension challenges
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Qualitative adjustments to visitation challenges
Number of subjects: 62
Study: 34508027

Group type: EXPERIMENTAL
Intervention: Machine learning model using biomarkers (C-reactive protein and white blood cells) for prediction of culture-proven EOS.
Number of subjects: 1685

Group type: COMPARATOR
Intervention: Risk factors (RFs) alone for prediction of culture-proven EOS.
Number of subjects: 1685
Study: 34508298

Group type: EXPERIMENTAL
Intervention: Multiparametric MRI test with LiverMultiScan report
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Multiparametric MRI test
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Non-invasive evaluation of the liver with MRI or ultrasound-based elastography
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Non-invasive methods and visual reports
Number of subjects: 101
Study: 34508692

Group type: EXPERIMENTAL
Intervention: ESC 0/2h-algorithm using high-sensitivity cardiac troponin I (hs-cTnI) assay (ARCHITECT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ESC 0/1h-algorithm
Number of subjects: 0
Study: 34509298

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) used as tracer for pelvic lymphadenectomy and removal of upper paracervical lymphovascular tissue (UPLT)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Removal of UPLT
Number of subjects: 145
Study: 34509409

Group type: EXPERIMENTAL
Intervention: Patient-worn accelerometers measuring Physical Average Daily Activity (PADA)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Patient-worn accelerometers measuring Total Average Daily Activity
Number of subjects: 63
Study: 34509410

Group type: EXPERIMENTAL
Intervention: Management guided by pulmonary artery (PA) pressure monitoring
Number of subjects: 1200
Study: 34509588

Group type: EXPERIMENTAL
Intervention: EndoNaut 2D fusion imaging system
Number of subjects: 255

Group type: COMPARATOR
Intervention: Control group (without EndoNaut 2D fusion imaging)
Number of subjects: 255
Study: 34509774

Group type: EXPERIMENTAL
Intervention: Daytime sleepiness
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Insomnia disorder (ID)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Complex performance measures
Number of subjects: 89
Study: 34510123

Group type: EXPERIMENTAL
Intervention: Single nucleotide polymorphisms (SNPs) in 76 different genes
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Expression of genes in adult mouse stria vascularis and organ of Corti
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Potential genetic targets for SSNHL treatments
Number of subjects: 92
Study: 34510198

Group type: EXPERIMENTAL
Intervention: Human milk oligosaccharides (HMOs) among secretors
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Fucosyllacto-N-hexaose among secretors
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Difucosyllacto-N-hexaose among secretors
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Lacto-N-neotetraose (LNnT) among secretors
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Difucosyllactose among secretors
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Disialyllacto-N-hexaose and LNnT among non-secretors
Number of subjects: 107
Study: 34510295

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 556

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID with MTX > 15 mg/week
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID with MTX ≤ 15 mg/week
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID with MTX > 15 mg/week
Number of subjects: 556
Study: 34510361

Group type: EXPERIMENTAL
Intervention: Meloxicam prior to filgrastim
Number of subjects: 0

Group type: COMPARATOR
Intervention: Filgrastim only
Number of subjects: 0
Study: 34510377

Group type: EXPERIMENTAL
Intervention: Exercise training (ET) program consisting of supervised breathing, aerobic, strengthening, and stretching exercises for 8 weeks, 2 days a week
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Exercise training (ET) program
Number of subjects: 110
Study: 34510411

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 5299

Group type: EXPERIMENTAL
Intervention: Esketamine
Number of subjects: 5299
Study: 34510485

Group type: EXPERIMENTAL
Intervention: Frequent antibiotic courses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: House dust mite sensitization
Number of subjects: 0
Study: 34510716

Group type: EXPERIMENTAL
Intervention: Methylation marker panel using five markers
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Methylation marker panel
Number of subjects: 239
Study: 34511132

Group type: EXPERIMENTAL
Intervention: First-line crizotinib (n = 168)
Number of subjects: 235

Group type: COMPARATOR
Intervention: First-line chemotherapy (n = 67)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: First-line crizotinib (n = 168) with CD74-ROS1 fusions (n = 90)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: First-line crizotinib (n = 168) with non-CD74 ROS1 fusions (n = 69)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: First-line crizotinib (n = 168) with baseline brain metastasis (n = 45)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: First-line crizotinib (n = 168) without baseline brain metastasis (n = 123)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: First-line crizotinib (n = 168) with intracranial-only progression (n = 40)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: First-line crizotinib (n = 168) with extracranial-only progression (n = 64)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: First-line crizotinib (n = 168) with concomitant TP53 mutations (n = 13)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: First-line crizotinib (n = 168) with wild-type TP53 (n = 81)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: First-line crizotinib (n = 168) with concomitant driver mutations (n = 9)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: First-line crizotinib (n = 168) without concomitant mutations (n = 58)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: First-line crizotinib (n = 168) with concomitant tumor suppressor genes (n = 25)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: First-line crizotinib (n = 168) without concomitant tumor suppressor genes (n = 58)
Number of subjects: 235
Study: 34511898

Group type: COMPARATOR
Intervention: HRR after 6MWT categorized as HRR≤5 bt/min
Number of subjects: 2127

Group type: EXPERIMENTAL
Intervention: HRR after 6MWT categorized as HRR≥11 bt/min
Number of subjects: 2127

Group type: EXPERIMENTAL
Intervention: HRR≤10 bt/min after 6MWT
Number of subjects: 2127
Study: 34511974

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT)
Number of subjects: 210
Study: 34511975

Group type: COMPARATOR
Intervention: PE/low-PTX3
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: PE/high-PTX3
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: PR/low-PTX3
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: PR/high-PTX3
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: High-PTX3
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Combination of plasma PTX3 levels and PR
Number of subjects: 236
Study: 34512014

Group type: EXPERIMENTAL
Intervention: Accelerated Partial Breast Irradiation (APBI)
Number of subjects: 747
Study: 34512058

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Afatinib (deletion in exon 19 only)
Number of subjects: 59
Study: 34512305

Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 100
Study: 34513679

Group type: EXPERIMENTAL
Intervention: CD-19 CAR-T immunotherapy (second generation CAR containing CD28 or 4-1BB therapy)
Number of subjects: 1
Study: 34513681

Group type: EXPERIMENTAL
Intervention: Biodegradable rectal spacer balloon
Number of subjects: 24
Study: 34513946

Group type: EXPERIMENTAL
Intervention: Intermittent hypoxic-hyperoxic exposures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34513983

Group type: EXPERIMENTAL
Intervention: Tiotropium/olodaterol
Number of subjects: 0
Study: 34514286

Group type: EXPERIMENTAL
Intervention: Rice Bran (RB) dietary supplementation for 6 months
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no RB supplementation)
Number of subjects: 47
Study: 34514436

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 mRNA vaccines (Pfizer-BioNTech BNT162b2 or Moderna mRNA-1273)
Number of subjects: 96
Study: 34514841

Group type: EXPERIMENTAL
Intervention: Bifurcation PCI
Number of subjects: 5498
Study: 34514849

Group type: EXPERIMENTAL
Intervention: Intraprocedural stent thrombosis (IPST)
Number of subjects: 6006

Group type: COMPARATOR
Intervention: No intraprocedural stent thrombosis (IPST)
Number of subjects: 6006
Study: 34515101

Group type: EXPERIMENTAL
Intervention: High-definition (3D) catheter
Number of subjects: 100

Group type: COMPARATOR
Intervention: High-resolution (2D) catheter
Number of subjects: 100
Study: 34515148

Group type: EXPERIMENTAL
Intervention: T allele carriers
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Dietary intake (macronutrients)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Multiple regression analysis
Number of subjects: 70
Study: 34515154

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 41
Study: 34515215

Group type: EXPERIMENTAL
Intervention: HKT288 (0.3 mg/kg IV every 3 weeks)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: HKT288 (0.75 mg/kg cohort)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: HKT288 (0.3 mg/kg IV)
Number of subjects: 9
Study: 34515303

Group type: EXPERIMENTAL
Intervention: Healthful plant-based diet index (hPDI)
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Overall plant-based diet index (PDI)
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Unhealthful plant-based diet index (uPDI)
Number of subjects: 646
Study: 34515338

Group type: EXPERIMENTAL
Intervention: CAR T-cell therapy
Number of subjects: 79
Study: 34515544

Group type: EXPERIMENTAL
Intervention: Nonchemotherapy arm of Children's Oncology Group Study ARST1321
Number of subjects: 0
Study: 34515905

Group type: EXPERIMENTAL
Intervention: Higher education years
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Increased depression by CES-D score
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Increased tangible support
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Comorbidities
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Higher education years (adjusted)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Tangible social support (adjusted)
Number of subjects: 321
Study: 34515993

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy (mitomycin-C and 5-FU; gemcitabine; gemcitabine plus oxaliplatin; or capecitabine)
Number of subjects: 931

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy
Number of subjects: 931

Group type: COMPARATOR
Intervention: Adjuvant S-1 chemotherapy
Number of subjects: 931

Group type: COMPARATOR
Intervention: No postoperative adjuvant chemotherapy (surgery alone)
Number of subjects: 931
Study: 34516465

Group type: EXPERIMENTAL
Intervention: Nurse-Nurse Collaboration Scale
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Jefferson Scale of Attitudes Toward Physician-Nurse Collaboration
Number of subjects: 477
Study: 34516656

Group type: EXPERIMENTAL
Intervention: Patching
Number of subjects: 890

Group type: COMPARATOR
Intervention: Bilateral lateral rectus recession
Number of subjects: 890

Group type: COMPARATOR
Intervention: Lateral rectus recession and medial rectus plication
Number of subjects: 890
Study: 34516954

Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel (target dose 5 × 10^5 CAR T cells)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Number of subjects: 115
Study: 34516956

Group type: EXPERIMENTAL
Intervention: AEx (aerobic exercise at 65-70% of age-predicted maximum heart rate for 45 min)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: REx (resistance exercise, 1-set to failure on 12 exercises)
Number of subjects: 24

Group type: COMPARATOR
Intervention: CON (sedentary control)
Number of subjects: 24
Study: 34517118

Group type: EXPERIMENTAL
Intervention: Sleep-disordered breathing (SDB)
Number of subjects: 77

Group type: COMPARATOR
Intervention: No SDB (Control)
Number of subjects: 77
Study: 34517841

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg
Number of subjects: 32
Study: 34518090

Group type: EXPERIMENTAL
Intervention: Hyperuricemic group (SUA > 7 mg/dl in men, > 6 mg/dl in women)
Number of subjects: 6221

Group type: EXPERIMENTAL
Intervention: SUA levels
Number of subjects: 6221

Group type: EXPERIMENTAL
Intervention: Body Roundness Index (BRI)
Number of subjects: 6221

Group type: EXPERIMENTAL
Intervention: Body Shape Index (BSI)
Number of subjects: 6221

Group type: EXPERIMENTAL
Intervention: Various thresholds of elevated SUA levels
Number of subjects: 6221
Study: 34518162

Group type: EXPERIMENTAL
Intervention: Anti-VEGF therapy initiation during lockdown (16 March 2020 through 31 July 2020)
Number of subjects: 2229

Group type: COMPARATOR
Intervention: No treatment (sham-control arm data from Minimally Classic/Occult Trial)
Number of subjects: 2229
Study: 34518203

Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC)
Number of subjects: 3804
Study: 34518262

Group type: EXPERIMENTAL
Intervention: Patient education and exercise
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Reference cohort from the general population
Number of subjects: 1000
Study: 34518555

Group type: EXPERIMENTAL
Intervention: Children with ASD
Number of subjects: 94

Group type: COMPARATOR
Intervention: Children with typical development
Number of subjects: 94
Study: 34518951

Group type: EXPERIMENTAL
Intervention: Laparoscopic splenectomy and azygoportal disconnection (LSD)
Number of subjects: 115
Study: 34519109

Group type: EXPERIMENTAL
Intervention: Pantoprazole
Number of subjects: 724

Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 724

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 724

Group type: EXPERIMENTAL
Intervention: High PPI dose (≥ 20 OE/day)
Number of subjects: 724

Group type: COMPARATOR
Intervention: PPI use (general)
Number of subjects: 724

Group type: EXPERIMENTAL
Intervention: Omeprazole (≤20 OE/day)
Number of subjects: 724
Study: 34519331

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure variability (BPV) measured as a continuous variable and by tertile of standard deviation (SD) of systolic BP.
Number of subjects: 6759
Study: 34519356

Group type: COMPARATOR
Intervention: Continuous venovenous haemodiafiltration (CVVHDF)
Number of subjects: 1143

Group type: COMPARATOR
Intervention: Pre-dilution haemofiltration
Number of subjects: 1143

Group type: COMPARATOR
Intervention: Longer catheter (> 20 cm) targeting the right atrium
Number of subjects: 1143

Group type: COMPARATOR
Intervention: Surface-modified double-lumen catheter
Number of subjects: 1143

Group type: COMPARATOR
Intervention: Higher blood flow (≥ 250 mL/minute)
Number of subjects: 1143

Group type: COMPARATOR
Intervention: More and shorter hollow fibre filters
Number of subjects: 1143

Group type: COMPARATOR
Intervention: CVVHDF
Number of subjects: 1143

Group type: COMPARATOR
Intervention: CVVHD
Number of subjects: 1143

Group type: COMPARATOR
Intervention: Longer catheter
Number of subjects: 1143

Group type: COMPARATOR
Intervention: Surface-modified double-lumen catheters
Number of subjects: 1143
Study: 34519666

Group type: EXPERIMENTAL
Intervention: Video vignettes for the online intervention
Number of subjects: 109
Study: 34519686

Group type: EXPERIMENTAL
Intervention: Anesthesia depth assessed by Narcotrend monitoring before stimulation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Narcotrend index cutoff value of 41 or greater
Number of subjects: 12
Study: 34519690

Group type: EXPERIMENTAL
Intervention: Search-and-treat strategy combined with biomarker screening (pepsinogens I and II, gastrin-17) for atrophic gastritis
Number of subjects: 3453

Group type: EXPERIMENTAL
Intervention: Telephone invitations
Number of subjects: 3453

Group type: COMPARATOR
Intervention: Mail invitations
Number of subjects: 3453
Study: 34519823

Group type: EXPERIMENTAL
Intervention: Osteogenesis Imperfecta (OI)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Healthy Controls (HC)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Non-COL variants (OI)
Number of subjects: 90
Study: 34519839

Group type: EXPERIMENTAL
Intervention: anti-CD47 antibodies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: anti-CD47 antibodies + IFN-α
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SIRPαFc to block CD47
Number of subjects: 0
Study: 34519964

Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 0
Study: 34520127

Group type: EXPERIMENTAL
Intervention: Fluzone® Quadrivalent (IIV4) vaccine
Number of subjects: 239
Study: 34520411

Group type: EXPERIMENTAL
Intervention: 4-week intervention to reduce sedentary time (SED) embedded in a pulmonary rehabilitation program (PRP)
Number of subjects: 21
Study: 34520638

Group type: EXPERIMENTAL
Intervention: Systemic antidepressant treatments
Number of subjects: 124

Group type: COMPARATOR
Intervention: No systemic antidepressant treatments
Number of subjects: 124
Study: 34520807

Group type: EXPERIMENTAL
Intervention: Regular cannabis users
Number of subjects: 70

Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 70
Study: 34521057

Group type: EXPERIMENTAL
Intervention: Skills for Improving Distress Intolerance (SIDI)
Number of subjects: 374

Group type: COMPARATOR
Intervention: Supportive Counseling
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 374
Study: 34521113

Group type: EXPERIMENTAL
Intervention: mAb CAEL-101 (11-1F4) administered as a single intravenous infusion with escalating doses from 0.5 mg/m2 to 500 mg/m2 in phase 1a and as 4 weekly infusions in phase 1b.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: mAb CAEL-101 (11-1F4)
Number of subjects: 27
Study: 34521364

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI) as a risk factor for IDH
Number of subjects: 8475

Group type: EXPERIMENTAL
Intervention: Smoking as a risk factor for IDH
Number of subjects: 8475
Study: 34521376

Group type: EXPERIMENTAL
Intervention: Increased sitting time
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Increased prolonged sitting time (≥30 min)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Higher average sleep duration
Number of subjects: 108

Group type: COMPARATOR
Intervention: Higher average sitting time
Number of subjects: 108

Group type: COMPARATOR
Intervention: Higher average prolonged sitting time (≥30 min)
Number of subjects: 108
Study: 34521479

Group type: EXPERIMENTAL
Intervention: Cardiac POCUS curriculum (pre-training online module and hands-on training with Butterfly iQ ultrasound)
Number of subjects: 6
Study: 34521615

Group type: EXPERIMENTAL
Intervention: Counseling and reminders through SMS text messaging and phone calls
Number of subjects: 264

Group type: COMPARATOR
Intervention: Routine standard care
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Counseling (20-minute sessions with trained counselors and information leaflets)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Reminder SMS text messaging and phone calls (SMS 3 days prior and phone call 1 day prior to scheduled visits)
Number of subjects: 264
Study: 34521667

Group type: EXPERIMENTAL
Intervention: COVID-19 group (pregnant women who test positive for SARS-CoV-2)
Number of subjects: 86000

Group type: COMPARATOR
Intervention: Non-infected group (screening group)
Number of subjects: 86000

Group type: EXPERIMENTAL
Intervention: Web-based questionnaires based on validated instruments
Number of subjects: 86000

Group type: EXPERIMENTAL
Intervention: Short- and long-term health outcomes from Swedish health registers
Number of subjects: 86000

Group type: EXPERIMENTAL
Intervention: Qualitative interviews
Number of subjects: 86000
Study: 34521694

Group type: EXPERIMENTAL
Intervention: Genetic testing for FH
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Management of patients with polygenic hypercholesterolaemia
Number of subjects: 336

Group type: COMPARATOR
Intervention: Comparison of cholesterol levels
Number of subjects: 336
Study: 34521729

Group type: EXPERIMENTAL
Intervention: Circulating cell-free double-stranded DNA (ccf-dsDNA) levels in patients with rapid progression of IPF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Circulating cell-free double-stranded DNA (ccf-dsDNA) levels in patients with slow progression of IPF
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 34522028

Group type: EXPERIMENTAL
Intervention: Verlindamycin combined with all-trans-retinoic acid (ATRA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verlindamycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Retinoid-based multimodal differentiation therapy
Number of subjects: 0
Study: 34522093

Group type: EXPERIMENTAL
Intervention: Early Morning Symptoms of COPD Instrument (EMSCI)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Evaluating Respiratory Symptoms in COPD (E-RS™: COPD)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Nighttime Symptoms of COPD Instrument (NiSCI)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Self-reported Physical Activity Level (PAL) through Exercise as Vital Sign (EVS) and Yale Physical Activity Survey (YPAS)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Physician-assessed Physical Activity Level (PAL)
Number of subjects: 406
Study: 34522876

Group type: EXPERIMENTAL
Intervention: Virus-related cirrhosis
Number of subjects: 3533

Group type: COMPARATOR
Intervention: Alcohol-related cirrhosis
Number of subjects: 3533

Group type: EXPERIMENTAL
Intervention: Combined aetiology cirrhosis
Number of subjects: 3533
Study: 34523045

Group type: EXPERIMENTAL
Intervention: Management according to ophthalmic and systemic disease
Number of subjects: 9
Study: 34523118

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 2314
Study: 34523117

Group type: EXPERIMENTAL
Intervention: Working in partnership interventions
Number of subjects: 16257

Group type: EXPERIMENTAL
Intervention: Working in partnership as part of a multi-component intervention
Number of subjects: 16257

Group type: COMPARATOR
Intervention: Usual practice without partnership
Number of subjects: 16257

Group type: COMPARATOR
Intervention: Multi-component intervention without partnership
Number of subjects: 16257